NCT01825551View on ClinicalTrials.gov

The Effect of GCSF in the Treatment of ALS Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Granulocyte Colony Stimulating Factor

DRUG

Placebo

Trial Locations (1)

Unknown

Iranian Neurology Research Center of Tehran University of Medical Sciences, Tehran

All Listed Sponsors
lead

Tehran University of Medical Sciences

OTHER

NCT01825551 - The Effect of GCSF in the Treatment of ALS Patients | Biotech Hunter | Biotech Hunter